Vivos Therapeutics (NASDAQ:VVOS) Shares Up 6.9% – Here’s Why

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares were up 6.9% on Friday . The stock traded as high as $5.12 and last traded at $4.98. Approximately 227,933 shares changed hands during trading, a decline of 50% from the average daily volume of 458,018 shares. The stock had previously closed at $4.66.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Alliance Global Partners dropped their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and issued a $6.60 price objective on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.

Vivos Therapeutics Stock Performance

The firm’s 50 day moving average price is $3.34 and its two-hundred day moving average price is $2.81. The company has a market cap of $24.08 million, a P/E ratio of -0.88 and a beta of 7.67.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.